Table 1. Basic characteristics of patients with all possible high-risk factors.
| Characteristics | A1 (n=72,143) | A2 (n=14,979) | A3 (n=30,698) | B1 (n=5,121) | B2 (n=16,589) | B3 (n=7,746) | C (n=4,523) | Total (n=151,799) |
|---|---|---|---|---|---|---|---|---|
| Age (years), n (%) | ||||||||
| Median [IQR] | 63 [57–68] | 69 [62–76] | 71 [64–76] | 65 [58–71] | 66 [61–73] | 73 [65–80] | 68 [61–76] | 66 [60–72] |
| ≤55 | 12,986 (18.0) | 1,228 (8.2) | 1,540 (5.0) | 816 (15.9) | 1,572 (9.5) | 389 (5.0) | 492 (10.9) | 19,023 (12.5) |
| 56–65 | 32,186 (44.6) | 4,167 (27.8) | 7,502 (24.4) | 1,978 (38.6) | 5,910 (35.6) | 1,669 (21.5) | 1,403 (31.0) | 54,815 (36.1) |
| 66–75 | 22,944 (31.8) | 5,501 (36.7) | 12,819 (41.8) | 1,630 (31.8) | 6,426 (38.7) | 2,589 (33.4) | 1,469 (32.5) | 53,378 (35.2) |
| 76–85 | 3,790 (5.3) | 3,477 (23.2) | 8,022 (26.1) | 563 (11.0) | 2,352 (14.2) | 2,411 (31.1) | 891 (19.7) | 21,506 (14.2) |
| >85 | 237 (0.3) | 606 (4.0) | 815 (2.7) | 134 (2.6) | 329 (2.0) | 688 (8.9) | 268 (5.9) | 3,077 (2.0) |
| Race, n (%) | ||||||||
| White | 59,318 (82.2) | 10,310 (68.8) | 23,888 (77.8) | 3,737 (73.0) | 13,737 (82.8) | 5,344 (69) | 3,339 (73.8) | 119,673 (78.8) |
| Black | 9,272 (12.9) | 3,729 (24.9) | 4,711 (15.3) | 1,061 (20.7) | 1,728 (10.4) | 1,799 (23.2) | 800 (17.7) | 23,100 (15.2) |
| Others | 3,553 (4.9) | 940 (6.3) | 2,099 (6.8) | 323 (6.3) | 1,124 (6.8) | 603 (7.8) | 384 (8.5) | 9,026 (5.9) |
| Marriage, n (%) | ||||||||
| Married | 57,064 (79.1) | 9,965 (66.5) | 23,025 (75.0) | 3,438 (67.1) | 12,875 (77.6) | 4,994 (64.5) | 3,019 (66.7) | 114,380 (75.3) |
| Unmarried | 7,546 (10.5) | 2,216 (14.8) | 2,984 (9.7) | 843 (16.5) | 1,577 (9.5) | 1,145 (14.8) | 647 (14.3) | 16,958 (11.2) |
| Separated | 7,533 (10.4) | 2,798 (18.7) | 4,689 (15.3) | 840 (16.4) | 2,137 (12.9) | 1,607 (20.7) | 857 (18.9) | 20,461 (13.5) |
| T stage, n (%) | ||||||||
| T1 | – | 9,080 (60.6) | 16,693 (54.4) | – | – | 5,330 (68.8) | – | 31,103 (20.5) |
| T2 | 46,457 (64.4) | 5,899 (39.4) | 14,005 (45.6) | 2,411 (47.1) | 6,927 (41.8) | 2,416 (31.2) | 1,761 (38.9) | 79,876 (52.6) |
| T3 | 23,885 (33.1) | – | – | 2,336 (45.6) | 8,812 (53.1) | – | 2,225 (49.2) | 37,258 (24.5) |
| T4 | 1,801 (2.5) | – | – | 374 (7.3) | 850 (5.1) | – | 537 (11.9) | 3,562 (2.3) |
| PSA (ng/mL), n (%) | ||||||||
| <4 | 10,099 (14.0) | – | 2,615 (8.5) | – | 1,635 (9.9) | – | – | 14,349 (9.5) |
| 4–10 | 50,731 (70.3) | – | 18,716 (61.0) | – | 9,243 (55.7) | – | – | 78,690 (51.8) |
| 10–20 | 11,313 (15.7) | – | 9,367 (30.5) | – | 4,631 (27.9) | – | – | 25,311 (16.7) |
| 20–40 | – | 9,826 (65.6) | – | 3,306 (64.6) | 604 (3.6) | 4,093 (52.8) | 2,376 (52.5) | 20,205 (13.3) |
| >40 | – | 5,153 (34.4) | – | 1,815 (35.4) | 476 (2.9) | 3,653 (47.2) | 2,147 (47.5) | 13,244 (8.7) |
| GS, n (%) | ||||||||
| ≤7 | 72,143 (100.0) | 14,979 (100.0) | – | 5,121 (100.0) | – | – | – | 92,243 (60.8) |
| 8 | – | – | 19,603 (63.9) | – | 7,848 (47.3) | 4,090 (52.8) | 1,933 (42.7) | 33,474 (22.1) |
| 9 | – | – | 10,165 (33.1) | – | 8,183 (49.3) | 3,278 (42.3) | 2,314 (51.2) | 23,940 (15.8) |
| 10 | – | – | 930 (3.0) | – | 558 (3.4) | 378 (4.9) | 276 (6.1) | 2,142 (1.4) |
| Therapy, n (%) | ||||||||
| LT | ||||||||
| NLT | ||||||||
| RP | 54,124 (75.0) | 2,496 (16.7) | 5,896 (19.2) | 2,455 (47.9) | 8,313 (50.1) | 537 (6.9) | 1,179 (26.1) | 75,000 (49.4) |
| EBRT | 8,782 (12.2) | 6,723 (44.9) | 17,313 (56.4) | 1,265 (24.7) | 4,117 (24.8) | 3,572 (46.1) | 1,644 (36.3) | 43,416 (28.6) |
| Prostatectomy | 2,574 (3.6) | 528 (3.5) | 1,101 (3.6) | 371 (7.2) | 1,764 (10.6) | 382 (4.9) | 422 (9.3) | 7,142 (4.7) |
| Radiation | 4,918 (6.8) | 3,781 (25.2) | 4,450 (14.5) | 704 (13.7) | 1,291 (7.8) | 2,129 (27.5) | 816 (18.0) | 18,089 (11.9) |
| COT | 1,648 (2.3) | 1,097 (7.3) | 1,544 (5.0) | 300 (5.9) | 1,062 (6.4) | 871 (11.2) | 391 (8.6) | 6,913 (4.6) |
| NDT | 97 (0.1) | 354 (2.4) | 394 (1.3) | 26 (0.5) | 42 (0.3) | 255 (3.3) | 71 (1.6) | 1,239 (0.8) |
| Follow up (months) | ||||||||
| Median [IQR] | 57 [33–89] | 71 [37–109] | 68 [37–104] | 60 [32–91] | 62 [34–93] | 46 [24–81] | 51 [27–81] | 60 [33–93] |
A1: T3–4, PSA ≤20 ng/mL, GS 2–7; A2: T1–2, PSA >20 ng/mL, GS 2–7; A3: T1–2, PSA ≤20 ng/mL, GS 8–10; B1: T3–4, PSA >20 ng/mL, GS 2–7; B2: T3–4, PSA ≤20 ng/mL, GS 8–10; B3: T1–2, PSA ≥20 ng/mL, GS 8–10; C: T3–4, PSA >20 ng/mL, GS 8–10. IQR, interquartile range; PSA, prostate-specific antigen; GS, Gleason score; LT, local treatment; NLT, no local treatment; RP, radical prostatectomy; EBRT, external beam radiotherapy; COT, combined therapy; NDT, no definitive therapy.